GLP-1 program setup has two halves: the business build-out and the clinical protocols. This guide walks physicians and providers through both, plus the patient flow that ties them together.
Adding a GLP-1 service line is one of the most direct ways for a licensed physician, NP, or PA to grow a practice without heavy overhead. Patient demand for semaglutide and tirzepatide is high, the clinical evidence is strong, and most physicians and providers already hold the licensure they need to prescribe. What separates a program that runs well from one that stalls is the setup: the business decisions on one side, the clinical protocols on the other, and a patient flow that connects them. This guide covers both halves at a working level, so you can plan the program and see where the deeper training fits.
In This Article
Overview
A GLP-1 program is two things at once. It is a business — pricing, staffing, patient materials, an EMR, a follow-up system — and it is a clinical service that requires sound prescribing, patient selection, and monitoring. Physicians and providers who treat it as only one or the other tend to struggle. Build the operations without the clinical rigor and you carry avoidable risk. Nail the clinical side but skip the systems and patients drift after the first month. The setup below keeps both in view.
💼 The Business Half
⚕️ The Clinical Half
Business Setup
Most established physicians and providers should add weight management to their existing practice rather than buy into a franchise. You already have patient relationships, space, and licensure, and you keep full control without franchise fees or royalties. A few decisions do most of the work.
GLP-1 receptor agonists are not controlled substances, so no special DEA scheduling applies to prescribing them, but you still need to verify a handful of items with your state medical board: whether weight management services require a separate practice registration, and — for NPs and PAs — your state’s supervision or collaboration requirements before you prescribe independently. If you plan to use compounded semaglutide or tirzepatide, the rules are a separate and fast-moving matter; branded products follow standard prescribing, while compounding runs through 503A pharmacies and 503B outsourcing facilities under their own framework. This is an educational overview, not legal advice, so confirm current requirements with your state board and a healthcare attorney.
Note: This is an educational overview, not legal advice. Confirm current requirements with your state board and a healthcare attorney before launch.
Physicians hold full prescribing authority; NP and PA authority varies by state; RNs and MAs can administer injections under order, run intake, and handle follow-up check-ins but cannot prescribe. Many practices start with a single additional clinical hire — usually a nurse who owns day-to-day patient contact.
Set up a cash-pay program fee that covers consultations, follow-ups, and body composition assessments; an EMR that tracks weight and body composition over time; and patient materials that make the value visible. Weight management is predominantly cash-pay, which frees your program design from insurance constraints.
For a deeper look at regulations and staffing, see Medical Weight Management Practice Regulations and Managing Your Medical Weight Management Practice.
Clinical Foundation
GLP-1 receptor agonists mimic the body’s natural GLP-1 hormone, acting on appetite, gastric emptying, and glycemic control to produce meaningful weight loss. Semaglutide (available as the Wegovy injection and, since the FDA’s December 2025 approval, an oral tablet) is a GLP-1 receptor agonist; tirzepatide (Zepbound and Mounjaro) is a dual agonist that acts on both GIP and GLP-1 receptors. Orforglipron (Foundayo), approved by the FDA on April 1, 2026, adds a newer option: an oral, once-daily, non-peptide GLP-1 receptor agonist taken with or without food, without the fasting and water restrictions that oral semaglutide requires. Across the class, therapy is intended as an adjunct to a reduced-calorie diet and increased physical activity, not a replacement for them.
Semaglutide
GLP-1 receptor agonist
Tirzepatide
Dual GIP + GLP-1 receptor agonist
Orforglipron (Foundayo)
Non-peptide GLP-1 receptor agonist
These medications are appropriate for adults with obesity, or overweight with a weight-related comorbidity, who can participate in a supervised program. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and in anyone with known hypersensitivity to the drug — and those contraindications apply across the class, oral or injectable. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Dosing starts low and titrates up gradually to improve tolerability, and patients need clear expectations that response varies and takes time.
Class-wide contraindications: Personal or family history of medullary thyroid carcinoma • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) • Known hypersensitivity to the drug. Applies to all agents in the class, oral or injectable.
Patient Flow
A consistent patient experience is what turns prescriptions into a durable program. A workable flow looks like this:
Front desk sets expectations for the first visit and screens for basic eligibility.
Health history, current medications, and prior weight-loss attempts documented before the clinical visit.
Contraindication screening, labs, and body composition analysis to establish baseline and confirm candidacy.
Clinical profile determines which agent, starting dose, and program tier is appropriate.
Medication, administration, expected timeline, side effects, and how to reach the office.
Review progress, adjust dosing, and manage side effects on a set schedule — built into protocols, not left to chance.
Transition once the patient reaches goal. Retention and referrals follow from a supported, accountable experience.
The follow-up system is the part most practices underbuild. Decide up front what you will track and when — weight and body composition, relevant labs, blood pressure, reported symptoms, and adherence — and build that into your protocols.
Launch Timeline
Skip the part where you build every protocol and form from scratch. Writing your own dosing protocols, side-effect algorithms, intake forms, consent documents, and patient education — then keeping all of it current as guidance and regulations shift — can stretch a launch into months, and small gaps in a clinical protocol or a consent form carry real risk.
IAPAM’s Certified Medical Weight Management Provider™ (CWMP) program hands you those pieces already built and ready to adapt to your practice: the prescribing and monitoring protocols, the patient materials, the business systems, and ongoing compliance updates so you are not tracking the rules alone. You customize instead of create, and you open with a program that is clinically sound from day one.
📋 Protocols & Forms
Dosing protocols, side-effect algorithms, intake forms, and consent documents — built and ready to adapt.
👥 Patient Materials
Education materials and program documentation that make the value of your program visible to patients.
📈 Business Systems
Cash-pay pricing models, program packages, and revenue frameworks from practices that are already running.
🔄 Compliance Updates
Ongoing updates as guidance and regulations shift — so you are not tracking the rules alone.
If you want to start on the clinical side before committing, IAPAM’s free 1 CME GLP-1 training is a no-commitment introduction to prescribing GLP-1s for weight loss.
Key Takeaways
Two halves, both required. GLP-1 program setup has a business half and a clinical half; a strong program needs both.
Confirm checkpoints first. GLP-1s are not controlled substances, but scope of practice, state registration, and compounding rules still need to be confirmed before launch.
Know the contraindications. Class-wide: personal or family history of medullary thyroid carcinoma, MEN2, and hypersensitivity. GI side effects are the most common.
Adjunct, not replacement. Therapy works alongside diet and activity, with low-and-slow dose titration.
Build the follow-up system. A defined patient flow and follow-up cadence drive retention; full protocols and business systems come from formal training.
Frequently Asked Questions
GLP-1 receptor agonists are not controlled substances, so no special DEA scheduling applies. You prescribe under your existing state medical license. NPs and PAs should confirm their state’s supervision or collaboration requirements before prescribing independently.
Startup is modest for an existing practice because you already have space, licensure, and patients. The main investments are an EMR, patient materials, body composition analysis, and staff training. Most programs run cash-pay, so you are not building around insurance reimbursement.
In most states, yes, after a proper evaluation, though you must be licensed where the patient is located at the time of the visit and confirm your state’s rules for establishing the patient-provider relationship. Because GLP-1s are not controlled substances, the federal in-person requirement for controlled substances does not apply to them.
Adults with obesity, or overweight with a weight-related comorbidity, who can take part in a supervised program. Screen out patients with a personal or family history of medullary thyroid carcinoma, MEN2, or known hypersensitivity, and assess pregnancy status and GI history before prescribing.
Semaglutide is a GLP-1 receptor agonist, available as the Wegovy injection and an oral tablet. Tirzepatide, sold as Zepbound and Mounjaro, is a dual agonist that acts on both GIP and GLP-1 receptors. Dosing and titration differ, which is why drug-specific protocols matter.
You can begin with IAPAM’s free 1 CME GLP-1 training for a clinical foundation. For full dosing protocols, side-effect management, patient selection frameworks, and the business setup, the Certified Medical Weight Management Provider (CWMP) program provides the complete system.
The Best-Run Practices
Skip building from scratch. The Certified Medical Weight Management Provider™ (CWMP) program gives you the protocols, patient materials, and business systems — ready to adapt and open with on day one.
Free 1 CME GLP-1 Training
A no-commitment clinical introduction to prescribing GLP-1s for weight loss. Start here before committing to the full program.
Get Free Training →CWMP Certification
The complete system: dosing protocols, side-effect management, patient selection, business setup, and compliance updates.
View CWMP Program →GLP-1 Clinic Hub
The full guide to starting a GLP-1 weight loss clinic — regulations, marketing, managing, and more.
Back to Hub →